Last reviewed · How we verify
NCT05301699
Development and Validation of a Web-based Nomorgam to Predict Postoperative Complications
trial testing data analysis; validating the nomogram in Gastric Cancer in 582 participants. Completed in 30 March 2022.
30 March 2022
Quick facts
| Lead sponsor | Nanjing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 582 |
| Start date | 1 March 2021 |
| Primary completion | 30 March 2022 |
| Estimated completion | 30 March 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- data analysis; validating the nomogram
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Nanjing Medical University
Who can join
60 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of complications after gastrectomy remains high among elderly patients with gastric cancer. The investigators sought to establish and validate a web-based nomorgam for predicting total complications among elderly patients undergoing resection of gastric cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05301699
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Nanjing Medical University trials
Trials by the same sponsor.
- NCT07382375 — AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection · NA · not yet recruiting
- NCT07494474 — Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD · not yet recruiting
- NCT07482774 — Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma · not yet recruiting
- NCT07348328 — Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery · NA · not yet recruiting
- NCT07258394 — Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05301699 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing Medical University
- Last refreshed: 1 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05301699.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing